Itacitinib
- Generic Name
- Itacitinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23F4N9O
- CAS Number
- 1334298-90-6
- Unique Ingredient Identifier
- 19J3781LPM
- Background
Itacitinib has been used in trials studying the treatment of Melanoma, Carcinoma, Metastatic Cancer, Endometrial Cancer, and B-cell Malignancies, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-03-08
- Target Recruit Count
- 32
- Registration Number
- NCT05823571
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-12-13
- Target Recruit Count
- 27
- Registration Number
- NCT05757219
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Douglas Johnson
- Target Recruit Count
- 25
- Registration Number
- NCT05660421
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease
- Conditions
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT05561985
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
- Conditions
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT05364762
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 63
- Registration Number
- NCT05063110
- Locations
- 🇫🇷
Hôpital Avicenne, Bobigny, France
Itacitinib for the Prevention of Graft Versus Host Disease
- Conditions
- Interventions
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT04859946
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 74
- Registration Number
- NCT04789850
- Locations
- 🇫🇷
CH de Cornouaille, Quimper, France
🇫🇷CH Amiens, Amiens, France
🇫🇷CHU Angers, Angers, France
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 18
- Registration Number
- NCT04640025
- Locations
- 🇩🇪
University Hospital Mannheim, Mannheim, Germany
🇮🇹Azienda Policlinico Vittorio Emanuele, Catania, Italy
🇮🇹Aou San Giovanni Di Dio E Ruggi, Salerno, Italy
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 4
- Registration Number
- NCT04629508
- Locations
- 🇮🇹
Treviso Hospital, Treviso, Italy
🇺🇸Vanderbilt University, Nashville, Tennessee, United States
🇮🇹Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele, Milan, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.